SCHEMBL23306901

SCHEMBL23306901

Cn1c2ccncc2c2ccc(-c3cc4c(cn3)c3cnccc3n4C)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.39
MAPT P10636 4/20 0.37
MAOA P21397 5/20 0.37
MAOB P27338 5/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ACHE P22303 1/20 0.37
ATM Q13315 1/20 0.36
CYP2D6 P10635 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
CHEK1 O14757 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24299501 0.88 NPC1 (0.44) TOP2AMAPTMAOAMAOBNPC1
SCHEMBL22883537 0.88 TOP2A (0.46) TOP2AMAPTMAOAMAOBNPC1
SCHEMBL24436980 0.83 TOP2A (0.38) TOP2AMAOAMAOBNPC1RAB9A
SCHEMBL19731916 0.81 TOP2A (0.42) TOP2AMAPTMAOAMAOBNPC1
SCHEMBL22906917 0.81 ATM (0.50) TOP2AMAOAMAOBNPC1RAB9A
SCHEMBL27097179 0.81 TOP2A (0.43) TOP2AMAPTMAOAMAOBNPC1
SCHEMBL22906702 0.80 NPC1 (0.43) TOP2ANPC1RAB9APOLBGAA
SCHEMBL27097180 0.80 WNT3A (0.45) TOP2AMAPTNPC1RAB9APOLB
SCHEMBL29547590 0.80 MAPT (0.48) TOP2AMAPTNPC1RAB9APOLB
SCHEMBL14134198 0.80 MAPT (0.48) TOP2AMAPTNPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2023-12-05 US disclosed
US-20230026258-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2023-01-26 US disclosed
US-20220144869-A1 HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS UDC IRELAND LIMITED (IE) 2022-05-12 US disclosed
US-20210126207-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2021-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144869-A1 HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS OCIAD2, OCIAD1, CLTB TOP2A 4538/4885MAPT 58/4885MAOA 442/4885
US-20230026258-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS OCIAD1, OCIAD2, DRD2 TOP2A 4574/4885MAPT 893/4885MAOA 1877/4885
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS OCIAD1, OCIAD2, DRD2 TOP2A 4574/4885MAPT 893/4885MAOA 1877/4885
US-20210126207-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS OCIAD1, OCIAD2, DRD2 TOP2A 4574/4885MAPT 893/4885MAOA 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.